Iowa City, IA-Primary open-angle glaucoma (POAG) is a common ocular affliction, but because it is generally a late-onset disease, it is difficult to study molecularly, according to Wallace L.M. Alward, MD.
Q. Could you explain how a living trust works? Should I consider one as part of my estate planning?
Alameda, CA-InSite Vision Inc. has filed an investigational new drug application with the FDA for ISV-403, its treatment for ocular bacterial infections, under development with Bausch & Lomb.
Buffalo, NY-The former management team of Leica Microsystems Inc. and a private equity investment fund have purchased the Reichert Ophthalmic Instruments division and the analytical instrument business from Germany-based Leica to form Reichert Inc.
Atlanta-CIBA Vision Corp. executives have shuffled their roles as the
company prepares for what many
in the industry expect to be another year of increased sales.
It may not be any consolation to you, but many investors have become concerned about, or are now discouraged with, the performance of their investments. Standing by and watching years of savings and past gains slip away over a 2-year period has many people wondering what to do next. According to the September issue of the AARP Bulletin, more than $7 trillion has evaporated since this bear market started. Of this, about $700 billion disappeared in value within retirement savings. To give you another perspective, a dollar invested in the broad-based S&P 500 in March 2000 is now worth about 55 cents.
Monrovia, CA-STAAR Surgical has reached a settlement with former Chief Executive Officer John R. Wolf that resolves two pending court cases.
Nowadays, it is possible to lease almost anything. Leasing can be an excellent means to obtain use of an asset. It is important to understand the real benefits of leasing and to know how to determine under which circumstances leasing is the better choice.
Baltimore-Race, that ever-sensitive subject in American culture, was the focus of a day-long meeting, "Ethnicity & Glaucoma: The Past, Present, and Future," at Johns Hopkins' Bloomberg School of Public Health.
Irvine, CA-ISTA Pharmaceuticals Inc. has secured $44 million in financing, including a $4 million bridge loan, to complete development work on late-stage ophthalmic products in the company's clinical pipeline.